American Psychiatric Association. DSM-IV: Diagnostic and statistical manual of mental disorders. 4th ed., Washington: American Psychiatric Press, 1994.
American Psychiatric Association. Practice guidelines for the treatment of patients with panic disorder. Am J Psychiatry 1998;155(Suppl):1-34.
Blanco C, Schneier FR, Liebowitz MR. Pharmacotherapy for social phobia. In textbook of anxiety disorders. Stein DJ, Hollander E (Eds). Washington: American Psychiatric Publishing, 2002;309-21.
Lydiard RB. Pharmacotherapy for panic disorder. In textbook of anxiety disorders. Stein DJ, Hollander E (Eds). Washington: American Psychiatric Publishing, 2002; 257-71.
Sussman N, Stein DJ. Pharmacotherapy for generalized anxiety disorder. In textbook of anxiety disorders. Stein DJ, Hollander E (Eds). Washington: American Psychiatric Publishing, 2002; 135-9.
Kessler RC, Berglund P, Demler O, et al. Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the national comorbidity survey replication. Arch Gen Psychiatry 2005;62:593-602.
Alonso J, Angermeyer MC, Bernert S, et al. Prevalence of mental disorders in Europe: Results from the European study of the epidemiology of mental disorders (ESEMeD) project. Acta Psychiat Scand 2004;109 (Suppl. 420):21-7.
Spitzer RL, Williams JBW, Kroenke K, et al. Utility of a new procedure for diagnosing mental disorders in primary care. JAMA 1994;272:1749-56.
Ansseau M, Dierick M, Buntinkx F, et al. High prevalence of mental disorders in primary care. J Affective Disord 2004;78:49-55.
Perna G, Bertani A, Caldirola D, et al. A comparison of citalopram and paroxetine in the treatment of panic disorder: A randomized, single-blind study. Pharmacopsychiatry 2001;34:85-90.
Klein DF. Delineation of two drug-responsive anxiety syndromes. Psychopharmacologia 1964;5:397-408.
Benjamin J, Ben-Zion IZ, Karbofsky E, et al. Double-blind placebo-controlled pilot study of paroxetine for specific phobia. Psychopharmacology 2000;149:194-6.
Healy D. Have drugs companies hyped social anxiety disorder to increase sales? West J Med 2001;175:364.
Schneier FR, Marshall RD, Erwin BA, et al. Social phobia and specific phobias. In treatment of psychiatric disorders, 3rd ed., Gabbard G.O. (Ed.). Washington: American Psychiatric Press, 2001;2:1485-513.
Pélissolo A, Lépine JP. Epidemiology of depression and anxiety disorders. In ISRS in Depression and Anxiety. Perspectives in psychiatry. Montgomery SA, den Boer, JA (Eds). Chichester: Wiley, 1998;7:1-21.
Ansseau M, Fischler B, Dierick M, et al. Prevalence and impact of generalized anxiety disorder and major depression in primary care in Belgium and Luxemburg: The GADIS study. Eur Psychiatry 2005;20:229-35.
Hoehn-Saric R, Borkovec TD, Crits-Christoph P. Generalized anxiety disorder. In treatment of psychiatric disorders. 3rd ed. Gabbard GO (Ed.). Washington: American Psychiatric Press 2001;2:1587-622.
Barman Balfour JA, Jarvis B. Venlafaxine extended-release. A review of its clinical potential in the management of generalised anxiety disorder. CNS Drugs 2000;14:483-503.
